C&P Exam Prep Guide for AL amyloidosis (DC 7717)

Read the C&P exam preparation guideWhat happens at the exam, what 38 CFR Part 4 requires the examiner to record, and what to bring.
Build your prep packet for this conditionOrganize the codes, your symptoms, records, and a body-map into one printable sheet. Private to your device.
Diagnostic code: 7717Condition: AL amyloidosis (primary amyloidosis)Regulation: 38 CFR § 4.117DBQ: HEMIC Hematologic and Lymphatic Conditions Including Leukemia

YOUR EXAM BLUEPRINT

AL amyloidosis

A blood or lymphatic-condition exam mostly reviews your lab results and treatment. The rating depends on whether the condition is active or in remission and the treatment you need, under 38 CFR 4.117.

DC 7717

DBQ used for this condition

  • P
    DBQ HEMIC Hematologic and Lymphatic Conditions Including Leukemia
    Open the public DBQ
    Public form

What the examination is likely to focus on

History and interviewFatigue, weakness, frequent infections, or easy bruising and bleeding. The diagnosis (leukemia, lymphoma, anemia) and when it was made. Treatment: chemotherapy, transfusions, or medication, and whether the disease is active or in remission. Hospitalizations and the effect on daily life.
Physical examinationChecking for pale skin, bruising, enlarged lymph nodes, or an enlarged spleen. A general exam.
Diagnostic testingLab tests the examiner reviews to gauge severity. Complete blood count (CBC), Bone marrow biopsy, Blood smear.
Functional assessmentWhether the condition is active or in remission, the treatment required (continuous medication, transfusions), and your blood counts, which set the rating. Findings map to the tiers in 38 CFR 4.117 (e.g. leukemia DC 7703; non-Hodgkin's lymphoma DC 7715; anemia DC 7720).

Functional-impact topics to describe

  • Whether the condition is active or in remission, the treatment required (continuous medication, transfusions), and your blood counts, which set the rating.
  • Findings map to the tiers in 38 CFR 4.117 (e.g. leukemia DC 7703; non-Hodgkin's lymphoma DC 7715; anemia DC 7720).
This blueprint is preparation guidance, not a prediction of the examination or claim outcome.RateMyVSO.net

Which form the examiner uses

For al amyloidosis (DC 7717), the C&P examiner completes the following Disability Benefits Questionnaire (DBQ):

DBQs are Department of Veterans Affairs Form 21-0960 series documents. Public DBQs are hosted on benefits.va.gov. A handful are examiner-only and are not posted publicly.

The DBQ topics for this condition

These are the parts of the DBQ form that apply to AL amyloidosis (primary amyloidosis) (DC 7717). Sections the form uses for other conditions are left out. Topics marked Only if this applies depend on your own history, such as surgery, a device, or a complication; open one if it applies to you. Section and question numbers are the ones printed on the VA form.

Hematologic and Lymphatic Conditions, Including Leukemia

Open the full VA form (PDF, reference copy) Updated on: 2025-12-05

Section 1 Diagnosis Form page 1

Printed at the top of this section (1)
  • Note: These are condition(s) for which an evaluation has been requested on the exam request form (Internal VA) or for which the Veteran has requested medical evidence be provided for submission to VA.
  1. 1A. List the claimed condition(s) that pertain to this questionnaire:
    • Note: These are the diagnoses determined during this current evaluation of the claimed condition(s) listed above. If there is no diagnosis, if the diagnosis is different from a previous diagnosis for this condition, or if there is a diagnosis of a complication due to the claimed condition(s), explain your findings and reasons in the Remarks section. Date of diagnosis can be the date of the evaluation if the clinician is making the initial diagnosis or an approximate date determined through record review or reported history.
  2. 1B. Select diagnoses associated with the claimed condition(s) (check all that apply):
    Options printed on the form (40)
    • The Veteran does not have a current diagnosis associated with any claimed condition(s) listed above. (Explain your findings and reasons in the Remarks section)
    • Agranulocytosis, acquired
    • Leukemia
    • Chronic myelogenous leukemia (CML) (chronic myeloid leukemia or chronic granulocytic leukemia)
    • Chronic lymphocytic leukemia (CLL)
    • Hairy cell or other B-cell leukemia
    • Other
    • Specify:
    • Hodgkin's lymphoma
    • Non-Hodgkin's lymphoma (NHL)
    • Multiple myeloma
    • Monoclonal gammopathy of undetermined significance (MGUS)
    • Myelodysplastic syndrome
    • Solitary plasmacytoma
    • Anemia
    • Aplastic anemia
    • Iron deficiency anemia
    • Folic acid deficiency
    • Pernicious anemia or other Vitamin B12 deficiency anemia
    • Acquired hemolytic anemia
    • Other
    • Specify:
    • AL amyloidosis (primary amyloidosis)
    • Immune thrombocytopenia
    • Polycythemia vera
    • Sickle cell anemia
    • Splenectomy
    • Are there complications such as systemic infections with encapsulated bacteria?
    • If Yes, complete Section 6 - Other Pertinent Physical Findings, Complications, Conditions, Signs and/or Symptoms.
    • Injury to Spleen
      If checked, complete Section 6 - Other Pertinent Physical Findings, Complications, Conditions, Signs and/or Symptoms.
    • Adenitis, tuberculous (Also complete the Infectious Diseases (Other than
    • HIV-Related Illness, Chronic Fatigue Syndrome, or Tuberculosis) Disability
    • Benefits Questionnaire).
    • Active
    • Inactive
    • Essential thrombocythemia or primary myelofibrosis
    • Other, specify
    • Other diagnosis #1:
    • Other diagnosis #2:
    • Other diagnosis #3:
  3. 1C. If there are additional or prior diagnoses that pertain to hematologic or lymphatic conditions, list using above format:

Section 2 Medical History Form page 3

  1. 2A. Describe the history (including cause (if known), onset and course) of the Veteran's current hematologic or lymphatic condition(s) (brief summary):
  2. 2B. Is continuous medication required for control of a hematologic or lymphatic condition, including anemia or thrombocytopenia caused by treatment for a hematologic or lymphatic condition?
    • If yes, list only those medications required for control of the Veteran's hematologic or lymphatic condition, including anemia or thrombocytopenia caused by treatment for a hematologic or lymphatic condition. Provide the name of the medication and the condition the medication is used to treat:
  3. 2C. Has the Veteran completed any treatment or is the Veteran currently undergoing any treatment for any hematologic or lymphatic condition, including leukemia?
    • No; watchful waiting
    • If yes, indicate type of treatment the Veteran is currently undergoing or has completed in the applicable section(s) below.

Section 3 Anemia and Thrombocytopenia Form page 3

Only if this applies: Anemia or thrombocytopenia is diagnosed, including a treatment complication.
Printed at the top of this section (1)
  • Note: If treatment was provided beyond that specified under the specific diagnosis below, or if more than one course of treatment was provided, describe in the Remarks Section.
  1. 3A. Does the Veteran have anemia or thrombocytopenia including that which is caused by treatment for a hematologic or lymphatic condition?
    Options printed on the form (12)
    • If yes, please check type:
    • Aplastic anemia (complete 3B)
    • Iron deficiency anemia (complete 3C)
    • Folic acid deficiency (complete 3D)
    • Pernicious anemia or other Vitamin B12 deficiency anemia (complete 3E)
    • Acquired hemolytic anemia (complete 3F)
    • Immune thrombocytopenia (complete 3G)
    • Sickle cell anemia (complete 3H)
    • Other
    • Specify
    • Is the anemia caused by treatment for another hematologic or lymphatic condition?
    • If yes, provide the name of the other hematologic or lymphatic condition causing the secondary anemia:
  2. 3B. What is the status of aplastic anemia?
    Options printed on the form (9)
    • Requiring peripheral blood or bone marrow stem cell transplant
      If checked, provide the following:
    • Describe the type of transplant and date of hospitalization:
    • Date of hospital discharge following transplant (if known):
    • Requiring transfusion of platelets, on average, at least: once every six weeks per 12-month period once every three months per 12-month period once per 12-month period
    • Requiring transfusion of red cells, on average, at least: once every six weeks per 12-month period once every three months per 12-month period once per 12-month period
    • Infections recurring, on average, at least: once every six weeks per 12-month period once every three months per 12-month period once per 12-month period
    • Using continuous therapy with immunosuppressive agent
    • Using continuous therapy with newer platelet stimulating factors
    • Note: The term "newer platelet stimulating factors" includes medication, factors, or other agents approved by the United States Food and Drug Administration.
  3. 3C. What is the status of iron deficiency anemia?
    • Requiring intravenous iron infusions 4 or more times per 12-month period
    • Requiring intravenous iron infusions at least 1 time but less than 4 times per 12-month period
    • Requiring continuous treatment with oral supplementation
    • Requiring treatment only by dietary modification
    • Asymptomatic
  4. 3D. What is the status of folic acid deficiency?
    • Requiring continuous treatment with high-dose oral supplementation
    • Requiring treatment only by dietary modification
    • Asymptomatic
  5. 3E. What is the status of pernicious anemia or other vitamin B12 deficiency anemia?
    Options printed on the form (12)
    • Initial diagnosis requiring transfusion due to severe anemia
      If checked, provide the following:
    • Date of initial diagnosis requiring transfusion:
    • Date of hospital discharge following transfusion (if known):
    • Signs or symptoms related to central nervous system impairment, such as encephalopathy, myelopathy, or severe peripheral neuropathy, requiring parenteral
    • B12 therapy
      If checked, provide the following:
    • Describe signs/symptoms of central nervous system impairment:
    • Date of cessation of parenteral B12 therapy (if known):
    • Requiring continuous treatment with Vitamin B12 injections
    • Requiring continuous treatment with Vitamin B12 sublingual tablets
    • Requiring continuous treatment with high-dose Vitamin B12 oral tablets
    • Requiring continuous treatment with Vitamin B12 nasal spray or gel
    • Note: Following hospital discharge or cessation of parenteral B12 therapy, if there are any residual effects of pernicious anemia, such as neurologic involvement causing peripheral neuropathy, myelopathy, dementia, or related gastrointestinal residuals, also complete appropriate Questionnaire for each condition.
  6. 3F. What is the status of acquired hemolytic anemia?
    Options printed on the form (9)
    • Required a bone marrow transplant
      If checked, provide the following:
    • Date of hospitalization:
    • Date of hospital discharge following transplant (if known):
    • Requiring continuous intravenous or immunosuppressive therapy (e.g., prednisone, Cytoxan, azathioprine, or rituximab)
    • Requiring immunosuppressive medication 4 or more times per 12-month period
    • Requiring 2-3 courses of immunosuppressive therapy per 12-month period
    • Requiring one course of immunosuppressive therapy per 12-month period
    • Required a splenectomy
    • Asymptomatic
  7. 3G. What is the status of immune thrombocytopenia?
    Options printed on the form (12)
    • Requiring chemotherapy for chronic refractory thrombocytopenia
      If checked, provide the following:
    • Date treatment began:
    • Date of completion or anticipated date of completion of treatment (if known):
    • Requiring immunosuppressive therapy
    • Platelet count 30,000 or below despite treatment
    • Platelet count higher than 30,000 but not higher than 50,000 with history of hospitalization because of severe bleeding requiring intravenous immune globulin, high dose parenteral corticosteroids, and platelet transfusions
    • Platelet count higher than 30,000 but not higher than 50,000 with mild mucous membrane bleeding which requires oral corticosteroid therapy or intravenous immune globulin
    • Platelet count higher than 30,000 but not higher than 50,000 with immune thrombocytopenia which requires oral corticosteroid therapy or intravenous immune globulin
    • Platelet count higher than 30,000 but not higher than 50,000, not requiring treatment
    • Platelet count above 50,000 and asymptomatic
    • Required a splenectomy
    • In remission
  8. 3H. What is the status of sickle cell anemia?
    Options printed on the form (8)
    • With 4 or more painful episodes per 12-month period (occurring in skin, joints, bones, or any major organs) caused by hemolysis and sickling of red blood cells with anemia, thrombosis, and infarction; symptoms preclude light manual labor
    • With 3 painful episodes per 12-month period
    • With 1 or 2 painful episodes per 12-month period
    • Symptoms preclude other than light manual labor
    • Asymptomatic, established case in remission, but with identifiable organ impairment
    • Asymptomatic with no identifiable organ impairment
    • Other
    • Specify:

Section 4 Leukemia, Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance (mgus), Agranulocytosis, Acquired, Essential Thrombocythemia, Primary Myelofibrosis, and Myelodysplastic Syndromes Form page 6

Only if this applies: Leukemia, myeloma, MGUS, agranulocytosis, thrombocythemia, myelofibrosis or MDS is diagnosed.
Printed at the top of this section (3)
  • AGRANULOCYTOSIS, ACQUIRED, ESSENTIAL THROMBOCYTHEMIA, PRIMARY MYELOFIBROSIS, AND MYELODYSPLASTIC
  • SYNDROMES
  • Note: If treatment was provided beyond that specified under the specific diagnosis below, or if more than one course of treatment was provided, describe in the Remarks Section.
  1. 4A. Does the Veteran have leukemia, multiple myeloma, monoclonal gammopathy of undetermined significance (MGUS), agranulocytosis, acquired, essential thrombocythemia, primary myelofibrosis, or myelodysplastic syndromes?
    Options printed on the form (14)
    • If yes, please check type:
    • Chronic lymphocytic leukemia (complete 4B)
    • Monoclonal B-cell lymphocytosis (MBL) (complete 4B)
    • Hairy cell or other B-cell leukemia (complete 4B)
    • Chronic myelogenous leukemia (complete 4C)
    • Chronic myeloid leukemia (complete 4C)
    • Chronic granulocytic leukemia (complete 4C)
    • Multiple myeloma (complete 4D)
    • Monoclonal gammopathy of undetermined significance (MGUS) (complete 4D)
    • Agranulocytosis, acquired (complete 4E)
    • Essential thrombocythemia or primary myelofibrosis (complete 4F)
    • Myelodysplastic syndromes (complete 4G)
    • Other
    • Specify:
  2. 4B. What is the status of chronic lymphocytic leukemia, hairy cell leukemia, other B-cell leukemia, or monoclonal B-cell lymphocytosis?
    Options printed on the form (10)
    • Active (no treatment) (including Rai Stage I, II, III, or IV)
    • Undergoing treatment (chemotherapy, radiation therapy, surgical therapy, or other therapeutic procedures/treatment)
      If checked, provide the following:
    • Describe the type of treatment and date treatment began:
    • Anticipated date of completion of treatment (if known):
    • In remission, treatment completed
      If checked, provide the following:
    • Describe the type of treatment and date treatment began:
    • Date of completion of treatment (if known):
    • Note: If in remission and there are any residual effects following cessation of treatment for the above condition(s), also complete appropriate
    • Questionnaire for each condition.
    • Asymptomatic, Rai Stage 0
  3. 4C. What is the status of chronic myelogenous leukemia (CML) (chronic myeloid leukemia, or chronic granulocytic leukemia)?
    Options printed on the form (11)
    • Condition has undergone leukemic transformation (complete 4B)
    • Requiring peripheral blood or bone marrow stem cell transplant
      If checked, provide the following:
    • Describe the type of transplant and date of hospitalization:
    • Date of hospital discharge following transplant (if known):
    • Requiring continuous myelosuppressive or immunosuppressive therapy treatment
      If checked, provide the following:
    • Describe the type of treatment and date treatment began:
    • Date of completion or anticipated date of completion of treatment (if known):
    • Requiring intermittent myelosuppressive therapy, or molecularly targeted therapy with tyrosine kinase inhibitors, or interferon treatment when not in apparent remission
    • In apparent remission on continuous molecularly targeted therapy with tyrosine kinase inhibitors
    • In apparent remission with no active treatment or therapy
    • Asymptomatic
  4. 4D. What is the status of multiple myeloma?
    • Symptomatic
      If checked, provide date of diagnosis of symptomatic multiple myeloma:
    • Note: Current validated biomarkers of symptomatic multiple myeloma, asymptomatic, smoldering or monoclonal gammopathy of undetermined significance (MGUS) are acceptable for the diagnosis of multiple myeloma as defined by the American Society of Hematology (ASH) and International Myeloma Working Group (IMWG).
    • Smoldering multiple myeloma (SMM)
    • Monoclonal gammopathy of undetermined significance (MGUS)
    • Asymptomatic
  5. 4E. What is the status of agranulocytosis, acquired?
    Options printed on the form (14)
    • Requiring bone marrow transplant
      If checked, provide the following:
    • Date of hospital admission for bone marrow transplant:
    • Date of hospital discharge following transplant (if known):
    • Requiring intermittent myeloid growth factors (granulocyte colony-stimulating factor (G-CSF) to maintain absolute neutrophil count (ANC) greater than
    • 500/microliter (µl) but less than 1000/µl
    • Requiring granulocyte-macrophage colony-stimulating factor (GM-CSF)) to maintain ANC greater than 500/microliter (µl) but less than 1000/µl
    • Requiring continuous immunosuppressive therapy such as cyclosporine to maintain ANC greater than 500/microliter (μl) but less than 1000/μl
    • Requiring intermittent myeloid growth factors to maintain ANC greater than 1000/μl
    • Requiring intermittent use of a myeloid growth factor to maintain ANC greater than or equal to 1500/μl
    • Infections recurring, on average, at least once every six weeks per 12-month period
    • Infections recurring, on average, at least once every three months per 12-month period
    • Infections recurring, on average, at least once per 12-month period but less than once every three months per 12-month period
    • Requiring continuous medication (e.g., antibiotics) for control
    • Asymptomatic
  6. 4F. What is the status of essential thrombocythemia and primary myelofibrosis?
    Options printed on the form (13)
    • Condition has undergone leukemic transformation (complete 4B)
    • Requiring continuous myelosuppressive therapy
    • Requiring hospital admission for peripheral blood or bone marrow stem cell transplant
      If checked, provide the following:
    • Describe the type of transplant and date of hospitalization:
    • Date of hospital discharge following transplant (if known):
    • Requiring hospital admission for chemotherapy (including myelosuppressants) or interferon treatment
      If checked, provide the following:
    • Describe the type of treatment and date of hospitalization:
    • Date of completion or anticipated date of completion of treatment (if known):
    • Requiring continuous or intermittent myelosuppressive therapy, or chemotherapy, or interferon treatment for the purpose of maintaining platelet counts <500 ×
    • 10^9/L
    • Requiring continuous or intermittent myelosuppressive therapy, or chemotherapy, or interferon treatment for the purpose of maintaining platelet counts of 200,000-400,000
    • Requiring continuous or intermittent myelosuppressive therapy, or chemotherapy, or interferon treatment for the purpose of maintaining white blood cell (WBC) counts of 4,000-10,000
    • Asymptomatic
  7. 4G. What is the status of myelodysplastic syndromes?
    Options printed on the form (14)
    • Condition has undergone progression to leukemia (complete 4B)
    • Requiring peripheral blood or bone marrow stem cell transplant
      If checked, provide the following:
    • Describe the type of transplant and date of hospitalization:
    • Date of hospital discharge following transplant (if known):
    • Requiring chemotherapy
      If checked, provide the following:
    • Date treatment began:
    • Date of completion or anticipated date of completion of treatment (if known):
    • Requiring 4 or more blood or platelet transfusions per 12-month period
    • Requiring 1 to 3 blood or platelet transfusions per 12-month period
    • Infections requiring hospitalization 3 or more times per 12-month period
    • Infections requiring hospitalization 1 to 2 times per 12-month period
    • Requiring biologic therapy on an ongoing basis
    • Requiring erythropoiesis stimulating agent (ESA) for 12 weeks or less per 12-month period
    • Asymptomatic

Section 5 Lymphomas, Polycythemia Vera, and Solitary Plasmacytoma Form page 9

Only if this applies: Lymphoma, polycythemia vera or solitary plasmacytoma is diagnosed.
Printed at the top of this section (1)
  • Note: If treatment was provided beyond that specified under the specific diagnosis below, or if more than one course of treatment was provided, describe in the Remarks Section.
  1. 5A. Does the Veteran have Hodgkin's lymphoma, Non-Hodgkin's lymphoma, polycythemia vera or solitary plasmacytoma?
    Options printed on the form (7)
    • If yes, please check type:
    • Hodgkin's lymphoma (complete 5B)
    • Non-Hodgkin's lymphoma (NHL) (complete 5B)
    • Polycythemia vera (complete 5C)
    • Plasmacytoma (complete 5D)
    • Other
    • Specify:
  2. 5B. What is the status of the Hodgkin's lymphoma or Non-Hodgkin's lymphoma?
    Options printed on the form (9)
    • Active disease (no treatment)
    • Indolent and non-contiguous phase of low grade NHL
    • Undergoing treatment (chemotherapy, radiation therapy, surgical therapy, or other therapeutic procedures/treatment)
      If checked, provide the following:
    • Describe the type of treatment and date treatment began:
    • Anticipated date of completion of treatment (if known):
    • In remission, treatment completed
      If checked, provide the following:
    • Describe the type of treatment and date treatment began:
    • Date of completion of treatment (if known):
    • Asymptomatic
  3. 5C. What is the status of the polycythemia vera?
    Options printed on the form (17)
    • Condition has undergone leukemic transformation (complete 4B)
    • Requiring peripheral blood or bone marrow stem-cell transplant for the purpose of ameliorating the symptom burden
      If checked, provide the following:
    • Describe the type of transplant and date of hospitalization:
    • Date of hospital discharge following transplant:
    • Requiring chemotherapy (including myelosuppressants) for the purpose of ameliorating the symptom burden
      If checked, provide the following:
    • Date treatment began:
    • Date of completion or anticipated date of completion of treatment (if known):
    • Requiring phlebotomy 6 or more times per 12-month period for the purpose of controlling RBC count
    • Requiring phlebotomy 4-5 times per 12-month period to maintain platelets < 200,000 or white blood cells (WBC) < 12,000
    • Requiring phlebotomy 3 or fewer times per 12-month period to maintain all blood values at reference range levels
    • Requiring molecularly targeted therapy for the purpose of controlling RBC count
    • Requiring continuous biologic therapy or myelosuppressive agents, to include interferon, to maintain platelets < 200,000 or white blood cells (WBC) < 12,000
    • Requiring biologic therapy or interferon on an intermittent basis as needed to maintain all blood values at reference range levels
    • Asymptomatic
    • Other
    • Describe:
    • Note: If there are complications due to polycythemia vera such as hypertension, gout, stroke or thrombotic disease, ALSO complete appropriate Questionnaire for each condition.
  4. 5D. What is the status of the solitary plasmacytoma?
    Options printed on the form (10)
    • Active disease (no treatment)
    • Developed into multiple myeloma (complete 4D)
    • Undergoing treatment (chemotherapy, radiation therapy, surgical therapy, or other therapeutic procedures/treatment (including autologous stem cell transplantation))
      If checked, provide the following:
    • Describe the type of treatment and date treatment began:
    • Anticipated date of completion of treatment (if known):
    • In remission, treatment completed
      If checked, provide the following:
    • Describe the type of treatment and date treatment began:
    • Date of completion of treatment (if known):
    • Asymptomatic
    • Note: If there are any residual effects (plasma cell dysplasia and/or adverse effects of medical treatment), also complete appropriate Questionnaire for each condition.

Section 6 Other Pertinent Physical Findings, Complications, Conditions, Signs, Symptoms, and Scars Form page 10

  1. 6A. Does the Veteran have any other pertinent physical findings, complications, conditions, signs or symptoms related to any conditions listed in the diagnosis section above?
    • If yes, describe (brief summary) (Also if indicated, complete the appropriate questionnaire for each condition):
  2. 6B. Does the Veteran have any scars or other disfigurement (of the skin) related to any conditions or to the treatment of any conditions listed in the diagnosis section?
    • If yes, also complete the appropriate dermatological questionnaire.

Section 7 Diagnostic Testing Form page 11

Printed at the top of this section (1)
  • Note: If testing has been performed and reflects Veteran's current condition, no further testing is required. When appropriate, provide most recent complete blood count.
  1. 7A. Has clinically relevant laboratory testing been performed or reviewed in conjunction with this examination?
    Options printed on the form (11)
    • If yes, provide results:
    • Hemoglobin (HgB) (gm/dL):
    • Date:
    • Hematocrit (HCT) %:
    • Date:
    • Red blood cell (RBC) count:
    • Date:
    • White blood cell (WBC) count:
    • Date:
    • Platelet count (K/µL):
    • Date:
  2. 7B. Are there any other clinically relevant diagnostic test findings or results related to the claimed condition(s) and/or diagnosis(es), that were reviewed in conjunction with this examination?
    • If yes, provide type of test or procedure, date and results (brief summary):
  3. 7C. If any test results are other than normal, indicate relationship of abnormal findings to diagnosed conditions:

Section 8 Functional Impact Form page 11

Printed at the top of this section (1)
  • Note: Provide the impact of only the diagnosed condition(s), without consideration of the impact of other medical conditions or factors, such as age.
  1. 8A. Regardless of the Veteran's current employment status, do the conditions listed in the diagnosis section impact his/her ability to perform any type of occupational task (such as standing, walking, lifting, sitting, etc.)?
    • If yes, describe the functional impact of each condition, providing one or more examples:

Section 9 Remarks Form page 12

Only if this applies: Additional explanation or examination limitations need to be recorded.
  1. 9A. Remarks (if any - please identify the section to which the remark pertains when appropriate).

1 other section of this form covers other conditions, the examiner's signature, or answers you gave above, and is not part of this prep view. The examiner still works from the whole form.

This is a preparation view built from the current public VA forms. It is not an official VA crosswalk, it does not decide which exam VA orders, and it does not tell the examiner to skip anything. Measurements, diagnoses and opinions on the form are the examiner's to record.

What to expect at your C&P exam

A blood or lymphatic-condition exam mostly reviews your lab results and treatment. The rating depends on whether the condition is active or in remission and the treatment you need, under 38 CFR 4.117.

1Initial interview (history)

  • Fatigue, weakness, frequent infections, or easy bruising and bleeding.
  • The diagnosis (leukemia, lymphoma, anemia) and when it was made.
  • Treatment: chemotherapy, transfusions, or medication, and whether the disease is active or in remission.
  • Hospitalizations and the effect on daily life.

2Physical examination

  • Checking for pale skin, bruising, enlarged lymph nodes, or an enlarged spleen.
  • A general exam.

3Diagnostic tests the examiner may rely on

Lab tests the examiner reviews to gauge severity.

Complete blood count (CBC) what's this?
Measures red cells, white cells, and platelets.
Bone marrow biopsy what's this?
A sample of marrow examined to diagnose blood and marrow disorders.
Blood smear
Blood examined under a microscope to look at the cells.

4Functional assessment

  • Whether the condition is active or in remission, the treatment required (continuous medication, transfusions), and your blood counts, which set the rating.
  • Findings map to the tiers in 38 CFR 4.117 (e.g. leukemia DC 7703; non-Hodgkin's lymphoma DC 7715; anemia DC 7720).

Test explainers open MedlinePlus (NIH National Library of Medicine), or Wikipedia where MedlinePlus has no matching page. This describes what happens and what is measured, not how to influence a result.

Rating Levels for DC 7717

The following tiers are reproduced from 38 CFR Part 4, the VA Schedule for Rating Disabilities. Toggle between the official VA criteria and a Plain English explanation.

Plain-English summaries are AI-generated to explain the official criteria. The official 38 CFR language is the binding legal standard. When in doubt, ask a VSO.

Evidence cited in published BVA decisions for DC 7717

Each row counts the issues for this diagnostic code that the Board granted or denied and whose decision text discussed that type of evidence. An issue is one condition the Board ruled on, and one decision can contain several. Remanded issues are not included. This is a count from the public record, not a prediction or a recommendation for any claim.

  • Service treatment records: discussed in 45 granted or denied BVA issues (16 granted; 29 denied)
  • Buddy / lay statements: discussed in 25 granted or denied BVA issues (7 granted; 18 denied)
  • Medical literature: discussed in 7 granted or denied BVA issues (3 granted; 4 denied)

Disclaimer: This page reproduces public Department of Veterans Affairs forms (DBQs) and verbatim text from 38 CFR Part 4 (the VA Schedule for Rating Disabilities). It is informational only and is not legal or medical advice. For guidance on a specific claim, contact a VA-accredited representative.